About the BRC

The NIHR Great Ormond Street Hospital Biomedical Research Centre (BRC) supports medical research for children and young people at Great Ormond Street Hospital (GOSH) and the UCL Institute of Child Health (ICH).

GOSH and the ICH were first awarded BRC status by the National Institute for Health Research (NIHR) in 2007 and, in 2016, we secured £37 million for our third term, running to March 2022.

The funding enables basic scientific discoveries made in laboratories to be translated into ‘first in man’ or ‘first in child’ clinical studies. Our research aims to accelerate discoveries into the basis of childhood rare diseases and to develop new diagnostics, imaging techniques and treatments, including cellular and gene therapies.

Our BRC is ideally positioned to deliver this, as GOSH is the largest recipient of nationally commissioned NHS services in the UK - we are the only paediatric BRC.

For our third term, we will focus on four major Research Themes:

Gene, stem and cellular therapies aims to refine, advance and expand our state-of-the-art infrastructure to enable the delivery of new gene and cell therapies into the NHS.

Genomics and systems medicine aims to further develop personalised medicine for the NHS.

Novel therapies and their translation into childhood diseases aims to initiate and conduct high quality clinical trials in our rare disease population.

Advanced treatments for structural malformation and tissue damage aims pioneer advanced treatments, such as regenerative medicine, and develop new devices to provide therapeutic options for children with congenital malformations and tissue damage.

All activity at the NIHR GOSH BRC is underpinned by four Cross-cutting Themes:

GOSH rare disease cohorts aims to carefully define cohorts of patients to maximise health informatics data and sample collection, and better inform novel diagnostics and therapeutic interventions.

BRC experimental medicine academy invests in training and education for both non-clinical and clinical professionals including medics and allied health professionals.

Clinical Research Facility (CRF) funding from the BRC supports high intensity, early-phase clinical trials which require inpatient or intensive care accommodation. Support will be in the form of a team consisting of an Advanced Nurse Practitioner and research nurses.

Translation research and enterprise accelerator aims to accelerate partnerships through initiatives such as support in intellectual property (IP) protection, trial design, ‘match making’ with industrial partners and facilitating licencing agreements.